Navigation Links
IsoTis Reports Status of Merger Vote

Less Than 100,000 Additional "FOR" Votes Required for Integra Merger

IRVINE, California, October 26 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today reported that less than 100,000 votes "FOR" are needed to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007.

Today's special meeting of stockholders will remain open throughout the day to allow for additional votes to be cast. If insufficient votes are cast in favor of the Integra merger at today's meeting, IsoTis will adjourn the meeting to October 30, 2007.

Of the approximately 3.7 million shares present in person or by proxy at today's meeting, approximately 3.5 million shares voted "for" the merger with Integra, representing approximately 94.4% of the votes cast to date and approximately 49.0% of all outstanding shares at the record date.

The IsoTis Board of Directors continues to believe unanimously that the interests of IsoTis' stockholders are best served by the acquisition by Integra, and that there are no feasible alternatives for the company and its stockholders. If IsoTis is unable to obtain the vote necessary to approve the proposed transaction, the company believes it will have to seek bankruptcy protection.

About IsoTis

IsoTis is an orthobiologics company that develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. IsoTis' current orthobiologics products are bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. IsoTis' current commercial business is highlighted by its Accell line of products, which the company believes represents the next generation in bone graft substitution.

On August 7, 2007 Integra and IsoTis announced that they have reached a definitive agreement to create a global orthobiologics leader. The combination would create a comprehensive orthobiologics portfolio, one of the largest sales organizations focused on orthobiologics in the US, and multiple cross-selling opportunities. The transaction is subject to approval of IsoTis' stockholders, as well as other closing conditions and approvals. Upon closing, IsoTis will become a wholly-owned subsidiary of Integra and Integra will be one of the largest companies in the world focused on advanced technology in orthobiologics.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including those that refer to management's plans and expectations for, among other things, future operations, strategies, prospects, performance and financial condition and IsoTis' proposed acquisition by Integra. Words such as "strategy," "expects," "plans," "anticipates," "believes," "may," "will," "might," "could," "would," "continues," "estimates," "intends," "pursues," "projects," "goals," "targets" or the negative or other variations thereof and other words of similar meaning are intended to identify such forward-looking statements. One can also identify them by the fact that they do not relate strictly to historical or current facts. Such statements are based on the current expectations and projections of the management of IsoTis only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of IsoTis. Actual results could differ materially from current expectations and projections. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. IsoTis undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

A special stockholder meeting was convened on October 11, 2007, adjourned to October 23, 2007 and again adjourned to October 26, 2007 to obtain stockholder approval of the proposed transaction. IsoTis has filed with the Securities and Exchange Commission and distributed to its stockholders a definitive proxy statement and other relevant documents in connection with the special stockholder meeting for the proposed transaction. IsoTis stockholders are urged to read the definitive proxy statement and other relevant materials when they become available because they will contain important information about IsoTis, Integra and the proposed transaction. Investors may obtain a free copy of these materials and other documents filed by IsoTis with the Securities and Exchange Commission at the SEC's website at, at IsoTis' website at or by sending a written request to IsoTis at 2 Goodyear, Irvine, California 92618, Attention: Chief Financial Officer.

IsoTis and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in favor of the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of IsoTis' stockholders in connection with the proposed transaction will be set forth in IsoTis' revised definitive proxy statement for its special meeting. Additional information regarding these individuals and any interest they have in the proposed transaction is set forth in the revised definitive proxy statement when it is filed with the SEC.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
(Date:10/12/2015)... ... , ... NeuMedics Inc., is a specialty biopharmaceutical company focused on identifying and ... be administered as an eye drop, announced today it has been selected to present ... place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio. The ...
(Date:10/11/2015)... ... October 11, 2015 , ... ... has been officially launched and multiple surgeries have been completed with this new ... of the Neuroscience & Spine Center of the Carolinas. The Revolution™ Spinal ...
(Date:10/10/2015)... 10. Oktober, 2015 Am 8. Oktober ... Demokratischen Partei für Kalifornien) ihre Würdigung der International ... in die Aufzeichnungen des Kongresses eintragen lassen. Die ... Association (PPTA) und ihren Mitgliedsunternehmen unterstützt. Ihre ... des Bewusstseins über Plasmaspenden weltweit , Würdigung ...
(Date:10/9/2015)... Governor Tom Wolf announced today that Adaptimmune ... T-cell receptor cancer immunotherapy treatments, will create at least ... Pennsylvania , and today,s announcement ... high-paying jobs will be created with this project," said ... sustained funding for the life science sector and increased ...
Breaking Biology Technology:
(Date:9/24/2015)... 24, 2015 Publiceringsförbud ... Kerv ( ), ... idag världens första kontaktlösa betalningsring på ... 000 GBP för massproduktion via crowdfunding.  ... , Kerv-bärare kan göra direkta ...
(Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
(Date:9/10/2015)... Sept. 10, 2015 Pursuant Health has ... to create an interactive, image-based health risk assessment ... wellness kiosk.  The unique assessment quantifies user results ... that suggests an individual,s biological age based on ... measured by the kiosk. Comprised of ...
Breaking Biology News(10 mins):